Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Bayer has invested heavily in finerenone in kidney disease, but the window of opportunity has narrowed. Data will soon show whether it has shut completely.
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
Merck & Co and Bayer’s vericiguat was deemed another “win” for heart failure at a medical conference this weekend. But widespread use looks unlikely.